Description
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date
Date | Announcements |
---|---|
September 25, 2023 | ResMed Announces Results for the Fourth Quarter of FY2023 |
September 25, 2023 | Dividend/Distribution - RMD |
September 25, 2023 | Statement of CDIs on issue - RMD |
September 25, 2023 | RMD to Report Fourth Quarter Fiscal 2023 Results |
September 25, 2023 | Statement of CDIs on issue - RMD |
September 25, 2023 | Statement of CDIs on issue - RMD |
September 25, 2023 | FORM SD |
September 25, 2023 | Update - Dividend/Distribution - RMD |
September 25, 2023 | Statement of CDIs on issue - RMD |
September 25, 2023 | FORM 10Q for Qtr ended March, 2023 |
September 25, 2023 | ResMed Announces Results for the Third Quarter of FY2023 |
September 25, 2023 | Dividend/Distribution - RMD |
September 25, 2023 | RMD to Report Third Quarter Fiscal 2023 Results |
September 25, 2023 | Statement of CDIs on issue - RMD |
September 25, 2023 | Company Secretary Appointment/Resignation |
September 25, 2023 | Statement of CDIs on issue - RMD |
September 25, 2023 | Update - Dividend/Distribution - RMD |
September 25, 2023 | Statement of CDIs on issue - RMD |
September 25, 2023 | FORM 10Q for Qtr ended December, 2022 |
September 25, 2023 | ResMed Announces Results for the Second Quarter of FY2023 |
Load More
Load Less
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
EPS (Basic) | $ |
|
|
|
|
6.32 | 6.32 | 6.32 |
|
|
|
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Date | keys |
---|---|
08 March 2023 | Update on Indonesian subsidiary PT Bank Commonwealth Update on Indonesian subsidiary PT Bank Commonwealth |
09 March 2023 | ASB 2023 Half Year Financial Results Media Release |
RVN · NASDAQ
Rivian,Inc
AUD $60.14
-3.56 (-1.581%)
RVN · NASDAQ
Rivian,Inc
AUD $60.14
-3.56 (-1.581%)
RVN · NASDAQ
Rivian,Inc
AUD $60.14
-3.56 (-1.581%)
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.